These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 23114151)
1. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia]. Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151 [TBL] [Abstract][Full Text] [Related]
2. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374 [TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504 [TBL] [Abstract][Full Text] [Related]
4. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979 [TBL] [Abstract][Full Text] [Related]
5. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197 [TBL] [Abstract][Full Text] [Related]
6. [Studying of clinical and laboratory features of chronic eosinophilic leukemias /hypereosinophilic syndrome]. Zhang Y; Yu MH; Xu SC; Yang L; Yu Y; Hao YS; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):3-8. PubMed ID: 18512307 [TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study. Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396 [TBL] [Abstract][Full Text] [Related]
8. FIP1L1-PDGFRA positive chronic eosinophilic leukemia in Tunisian patients. Menif S; Omri H; Hafsia R; Ben Romdhane N; Turki S; Meddeb B; Dellagi K Pathol Biol (Paris); 2007 Jun; 55(5):242-5. PubMed ID: 17137731 [TBL] [Abstract][Full Text] [Related]
9. Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia. Cools J; Stover EH; Gilliland DG Methods Mol Med; 2006; 125():177-87. PubMed ID: 16502585 [TBL] [Abstract][Full Text] [Related]
10. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review. Savage N; George TI; Gotlib J Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324 [TBL] [Abstract][Full Text] [Related]
11. A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint. Lambert F; Heimann P; Herens C; Chariot A; Bours V J Mol Diagn; 2007 Jul; 9(3):414-9. PubMed ID: 17591942 [TBL] [Abstract][Full Text] [Related]
12. Detection of FIP1L1-PDGFRA fusion by FISH. Ma ES; Wong KF; Wong CL; Siu LL Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982 [No Abstract] [Full Text] [Related]
13. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report. Rodzaj M; Gałazka K; Majewski M; Zduńczyk A Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473 [TBL] [Abstract][Full Text] [Related]
14. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Shomali W; Gotlib J Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623 [TBL] [Abstract][Full Text] [Related]
15. A novel acquired cryptic three-way translocation t(2;11;5)(p21.3;q13.5;q23.2) with a submicroscopic deletion at 11p14.3 in an adult with hypereosinophilic syndrome. Kjeldsen E Exp Mol Pathol; 2015 Aug; 99(1):50-5. PubMed ID: 25962659 [TBL] [Abstract][Full Text] [Related]
16. [Identification of FIP1L1-PDGFRA fusion, and expression of signal transducer and activator of transcription 5 in hypereosinophilic syndrome]. Zhang GS; Li B; Pei MF; Dai CW; Zheng WL; Shen JK Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1541-4. PubMed ID: 15500716 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453 [TBL] [Abstract][Full Text] [Related]
18. A complex and cryptic intrachromosomal rearrangement generating the FIP1L1_PDGFRA in adult acute myeloid leukemia. Coccaro N; Anelli L; Orsini P; Zagaria A; Minervini A; Impera L; Tota G; Minervini CF; Cumbo C; Parciante E; Coserva MR; Attolico I; Specchia G; Albano F Cancer Genet; 2019 Nov; 239():8-12. PubMed ID: 31450116 [TBL] [Abstract][Full Text] [Related]
19. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Yamada Y; Rothenberg ME; Lee AW; Akei HS; Brandt EB; Williams DA; Cancelas JA Blood; 2006 May; 107(10):4071-9. PubMed ID: 16418325 [TBL] [Abstract][Full Text] [Related]
20. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]